Patents by Inventor Christine Esau
Christine Esau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912997Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Superoxide Dismutase 1 (SOD1) gene. The SOD1 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an SOD1 gene. Pharmaceutical compositions that include one or more SOD1 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described SOD1 RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of SOD1 gene expression and a reduction in SOD1 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including amyotrophic lateral sclerosis (ALS.).Type: GrantFiled: June 14, 2023Date of Patent: February 27, 2024Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Christine Esau, Ji Young Suk, Tao Pei, Anthony Nicholas, Xiaokai Li, Jeffrey Carlson
-
Publication number: 20240026363Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Superoxide Dismutase 1 (SOD1) gene. The SOD1 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an SOD1 gene. Pharmaceutical compositions that include one or more SOD1 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described SOD1 RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of SOD1 gene expression and a reduction in SOD1 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including amyotrophic lateral sclerosis (ALS.Type: ApplicationFiled: June 14, 2023Publication date: January 25, 2024Inventors: Christine Esau, Ji Young Suk, Tao Pei, Anthony Nicholas, Xiaokai Li, Jeffrey Carlson
-
Patent number: 11685921Abstract: This invention encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting Hepatitis B virus in a subject. The compounds have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, and the compounds are targeted to a sequence of an HBV genome.Type: GrantFiled: December 20, 2019Date of Patent: June 27, 2023Assignee: Arcturus Therapeutics, Inc.Inventors: Pattraranee Limphong, Kiyoshi Tachikawa, Christine Esau, Padmanabh Chivukula
-
Publication number: 20230149310Abstract: Nucleic acid immunization is achieved by delivering a nucleic acid (NA), e.g., a mRNA or a DNA, encapsulated within a lipid-NA nanoparticle. The NA encodes an immunogenic compound of interest. The lipid-NA nanoparticle is effective for in vivo delivery of NA to a vertebrate cell, including upon administration to a subject. The lipid-NA nanoparticle are incorporated in pharmaceutical compositions for immunizing subjects against various diseases.Type: ApplicationFiled: April 1, 2019Publication date: May 18, 2023Inventors: Padmanabh CHIVUKULA, Priya KARMALI, Christine ESAU, Jerel VEGA, Yanjie BAO, Rajesh MUKTHAVARAM, Samantha MURPHY
-
Publication number: 20230001021Abstract: The present disclosure provides, among other things, polynucleotide constructs, compositions, and methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need thereof a composition comprising a polynucleotide construct comprising a 5? UTR, a codon optimized mRNA encoding an ornithine transcarbamylase, and a 3? UTR.Type: ApplicationFiled: October 22, 2020Publication date: January 5, 2023Inventors: Owen DALY, Kieu LAM, James HEYES, Richard HOLLAND, Christine ESAU, Ed YAWORSKI, Mary PRIEVE
-
Publication number: 20220387600Abstract: Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to treat certain diseases, such as liver fibrosis, e.g., in the setting of NASH or ASH.Type: ApplicationFiled: December 7, 2020Publication date: December 8, 2022Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Richard J. HOLLAND, Mark WOOD, Alan D. MARTIN, Christine ESAU, Margrit SCHWARZ, Xin YE, Alice Hoy Lam LI, Christopher Justin PASETKA, David CROWE, Steven TYLER
-
Publication number: 20220288214Abstract: Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. He conjugates are useful to treat certain diseases, such as acromegaly.Type: ApplicationFiled: October 23, 2020Publication date: September 15, 2022Applicant: GENEVANT SCIENCES GMBHInventors: Drew KONDRATOWICZ, James HEYES, Richard J. HOLLAND, Christine ESAU, Kevin MCCLINTOCK, Christopher Justin PASETKA, Mark WOOD, Alan D. MARTIN, Margrit SCHWARZ, David CROWE, Steven TYLER
-
Patent number: 10961535Abstract: This invention encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting Hepatitis B virus in a subject. The compounds have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, and the compounds are targeted to a sequence of an HBV genome.Type: GrantFiled: August 30, 2018Date of Patent: March 30, 2021Assignee: Arcturus Therapeutics, Inc.Inventors: Pattraranee Limphong, Kiyoshi Tachikawa, Christine Esau, Padmanabh Chivukula
-
Publication number: 20200131516Abstract: This invention encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting Hepatitis B virus in a subject. The compounds have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, and the compounds are targeted to a sequence of an HBV genome.Type: ApplicationFiled: December 20, 2019Publication date: April 30, 2020Inventors: Pattraranee LIMPHONG, Kiyoshi TACHIKAWA, Christine ESAU, Padmanabh CHIVUKULA
-
Patent number: 10301627Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: GrantFiled: November 15, 2017Date of Patent: May 28, 2019Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Publication number: 20190062744Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.Type: ApplicationFiled: September 6, 2018Publication date: February 28, 2019Applicant: Regulus Therapeutics Inc.Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
-
Publication number: 20180371463Abstract: This invention encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting Hepatitis B virus in a subject. The compounds have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, and the compounds are targeted to a sequence of an HBV genome.Type: ApplicationFiled: August 30, 2018Publication date: December 27, 2018Inventors: Pattraranee Limphong, Kiyoshi Tachikawa, Christine Esau, Padmanabh Chivukula
-
Patent number: 9994842Abstract: Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or elevated serum triglycerides, through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Further provided are methods for reducing hepatic steatosis or liver tissue triglyceride accumulation through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Such methods employ oligomeric compounds which hybridize with or sterically interfere with nucleic acid molecules comprising or encoding miR-122a. Such oligomeric compounds may include one or more modifications thereon, which may improve the activity, stability, or nuclease resistance of the oligomeric compound. These modified oligomeric compounds are used as single compounds or in compositions, including pharmaceutical compositions, to modulate or mimic the targeted nucleic acid comprising or encoding miR-122a.Type: GrantFiled: January 14, 2015Date of Patent: June 12, 2018Assignee: Regulus Therapeutics Inc.Inventors: Christine Esau, Sanjay Bhanot
-
Publication number: 20180127755Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: ApplicationFiled: November 15, 2017Publication date: May 10, 2018Applicants: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Patent number: 9845470Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: GrantFiled: October 26, 2016Date of Patent: December 19, 2017Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Publication number: 20170268002Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.Type: ApplicationFiled: April 4, 2017Publication date: September 21, 2017Applicant: Regulus Therapeutics Inc.Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
-
Publication number: 20170137811Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: ApplicationFiled: October 26, 2016Publication date: May 18, 2017Applicants: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Publication number: 20170137821Abstract: This invention encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting Hepatitis B virus in a subject. The compounds have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, and the compounds are targeted to a sequence of an HBV genome.Type: ApplicationFiled: January 20, 2017Publication date: May 18, 2017Inventors: Pattraranee Limphong, Kiyoshi Tachikawa, Christine Esau, Padmanabh Chivukula
-
Patent number: 9598693Abstract: Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activating in a cell.Type: GrantFiled: July 27, 2015Date of Patent: March 21, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventors: Christine Esau, Eric E. Swayze, Balkrishen Bhat, Garth A. Kinberger
-
Publication number: 20170037402Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.Type: ApplicationFiled: August 11, 2016Publication date: February 9, 2017Applicant: Regulus Therapeutics Inc.Inventors: Christine Esau, Bridget Gordon, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta